Werkgroep Cardiologische centra Nederland

REFRESH (Recruiting)

A Phase 3, Double-blind, Placebo-controlled and Open-label Efficacy and Long-term Safety Study of Firibastat (QGC001) Administered Orally, Once Daily, for Up to 48 Weeks in Patients with Difficult-to-treat/Resistant Hypertension
Medicine
Firibastat
Population
Primairy prevention cardiovasular disease
Phase
III
Starting year
2021

Director of Study

drs. H.G.R. Dorman (Cardioloog)
Roosendaal, Bravis ziekenhuis